Aguirre-Mardones C, Iranzo A, Vilas D, Serradell M, Gaig C, Santamaría J, Tolosa E. Prevalence and timeline of nonmotor symptoms in idiopathic rapid eye movement sleep behavior disorder. J Neurol 2015; 262: 1568-78.
Baekelandt V, Claeys A, Eggermont K, Lauwers E, De Strooper B, Nuttin B, et al. Characterization of lentiviral vector-mediated gene transfer in adult mouse brain. Hum Gene Ther 2002; 13(7): 841-53.
Bellucci A, Collo G, Sarnico I, Battistin L, Missale C, Spano P. Alpha-synuclein aggregation and cell death triggered by energy deprivation and dopamine overload are counteracted by D2/D3 receptor activation. J Neurochem 2008; 106(2): 560-77.
Bellucci A, Navarria L, Falari E, Zaltieri M, Bono F, Collo G, et al. Redistribution of DAT/α- synuclein complexes visualized by in situ proximity ligation assay in transgenic mice modeling early Parkinson’s disease. PLoS one 2011; 6(12): e27959.
Bengoa-Vergniory N, Robert RF, Wada-Martins R, Alegre-Abarrategui J. Alpha-synuclein oligomers: a new hope. Acta Neruopathol. 2017; 134(6): 819-38.
Berg D, Postuma RB, Adler CH, Bloem BR, Chan P, Dubois B, et al. MDS research criteria for prodromal Parkinson’s disease. Mov Disord 2015; 30(12) 1600-11
Beyer K, Ariza A. alpha-Synuclein posttranslational modification and alternative splicing as a trigger for neurodegeneration. Mol Neurobiol 2013; 47(2): 509-24.
Boeve BF, Dickson DW, Olson EJ, Shepard JW, Silber MH, Ferman TJ, et al. Insights into REM sleep behavior disorder pathophysiology in brainstem- predominant Lewy body disease. Sleep Med 2007; 8(1): 60–4.
Calo L, Wegrzynowicz M, Santivañez-Perez J, Grazia Spillantini M. Synaptic failure and α- synuclein. Mov Disord 2016; 31(2): 169-77.
Cannon JR, Geghman KD, Tapias V, Sew T, Dail MK, Li C, et al. Expression of human E46K- mutated alpha-synuclein in BAC-transgenic rats replicates early-stage Parkinson's disease features and enhances vulnerability to mitochondrial impairment. Exp Neurol 2013; 240: 44- 56.
Chadchankar H, Ihalainen J, Tanila H, Yavich L. Decresed reuptake of dopamine in the dorsal striatum in the absence of α-synuclein. Brain Res 2011; 1382:37-44.
Chartier-Harlin M-C, Kachergus J, Roumier C, Mouroux V, Douay X, Lincoln S, et al. α- synuclein locus duplication as a cause of familial Parkinson's disease. The Lancet 2001; 364(9440): 1167-9.
Cheng HC, Ulane CM, Burke RE. Clinical progression in Parkinson disease and the neurobiology of axons. Ann Neurol 2010; 67(6):715–25.
Conway KA, Lee SJ, Rochet JC, Ding TT, Williamson RE, Lansbury PT Jr. Acceleration of oligomerization, not fibrillization, is a shared property of both alpha-synuclein mutations linked to early-onset Parkinson’s disease: implications for pathogenesis and therapy. Proc Natl Acad Sci USA 2000; 97(2): 571–6.
Cronin KD, Ge D, Manninger P, Linnertz C, Rossoshek A, Orrison BM, et al. Expansion of the Parkinson disease-associated SNCA-Rep1 allele upregulates human alpha-synuclein in transgenic mouse brain. Hum Mol Genet 2009; 18(17): 3274-85.
Dauer W, Przedborski S. Parkinson's disease: mechanism and models. Neuron. 2003; 39(6): 889-909.
Di Maio R, Barrett PJ, Hoffman EK, Barrett CW, Zharikov A, Borah A, et al. α-Synuclein binds to TOM20 and inhibit mitochondrial protein import in Parkinson’s disease. Sci Transl Med 2016; 8(342): 342ra78.
Fearnley JM, Lees AJ. Ageing and Parkinson's disease: substantia nigra regional selectivity. Brain 1991; 114: 2283-301.
Fleming SM, Tetreault NA, Mulligan CK, Hutson CB, Masliah E, Chesselet MF. Olfactory deficits in mice overexpressing human wildtype α-synuclein. Eur J Neurosci 2008; 28(2): 247- 56.
Fountaine TM, Wade-Martins R. RNA interference-mediated knockdown of alpha-synuclein human dopaminergic neuroblastoma cells from MPP(+) toxicity and reduces dopamine transport. J Neurosci. Res. 2007; 85(2):351-63.
Fu Y, Yuan Y, Halliday G, Rusznák Z, Watson C, Paxinos G. A cytoarchitectonic and chemoarchitectonic analysis of the dopamine cell groups in the substantia nigra, ventral tegmental area, and retrorubral field in the mouse. Brain Struct Funct 2012; 217(2): 591-612.
Funato H, Miyoshi C, Fujiyama T, Kanda T, Sato M, Wang Z, et al. Forward-genetics analysis of sleep in randomly mutagenized mice. Nature 2016; 539(7629): 378–83.
García-Lorenzo D, Longo-Dos Santos C, Ewenczyk C, Leu-Semenescu S, Gallea C, Quattrocchi G, et al. The coeruleus/subcoeruleus complex in rapid eye movement sleep behaviour disorders in Parkinson’s disease. Brain 2013; 136(Pt 7): 2120–9.
Giasson BI, Duda JE, Quinn SM, Zhang B, Trojanowski JQ, Lee VM Neuronal alpha- synucleinopathy with severe movement disorder in mice expressing A53T human alpha- synuclein. Neuron 2002; 34(4): 521–33.
Goldman JG and Postuma R. Premotor and nonmotor features of Parkinson's disease. Curr Opin Neurol. 2014; 27: 434-41.
Han W, Liu Y, Mi Y, Zhao J, Liu D, Tian Q. Alpha-synuclein (SNCA) polymorphisms and susceptibility to Parkinson's disease: a meta-analysis. Am J Med Genet B Neuropsychiatr Genet 2015; 168B(2): 123-34.
Hansen C, Bjorklund T, Petit GH, Lundblad M, Murmu RP, Brundin P, et al. A novel alpha- synuclein-GFP mouse model displays progressive motor impairment, olfactory dysfunction and accumulation of alpha-synuclein-GFP. Neurobiol Dis 2013; 56: 145-55.
Ibáñez P, Bonnet AM, Débarges B, Lohmann E, Tison F, Pollak P, et al. Causal relation between α-synuclein gene duplication and familial Parkinson's disease. Lancet. 2004; 364(9440): 1169-71.
Ihse E, Yamakado H, van Wijk XM, Lawrence R, Esko JD, Masliah E. Cellular internalization of alpha-synuclein aggregates by cell surface heparan sulfate depends on aggregate conformation and cell type. Sci Rep 2017;7:9008.
Ikuta F, Yoshida Y, Ohama E, Oyanagi K, Takeda S, Yamazaki K, et al. Revised Pathophysiology on BBB Damage: The Edema as an ingeniously Provided Condition for Cell Motility and Lesion Repair. Acta Neuropathol Suppl 1983; 8: 103-10.
Janezic S, Threlfell S, Dodson PD, Dowie MJ, Taylor TN, Potgieter D, et al. Deficits in dopaminergic transmission precede neuron loss and dysfunction in a new Parkinson model. Proc Natl Acad Sci U S A 2013; 110(42): E4016-25.
Jellinger KA. A critical evaluation of current staging of alpha-synuclein pathology in Lewy body disorders. Biochim Biophys Acta 2009; 1792(7): 730-40.
Kirik D, Rosenblad C, Burer C, Lundberg C, Johansen TE, Muzyczka N, et al. Parkinson-like neurodegeneration induced by targeted overexpression of alpha-synuclein in the nigrostriatal system. J Neurosci 2002; 22(7): 2780-91.
Kobayakawa K, Kobayakawa R, Matsumoto H, Oka Y, Imai T, Ikawa M, et al. Innate versus learned odour processing in the mouse olfactory bulb. Nature 2007; 450(7169): 503-8.
Konno T, Ross OA, Puschmann A, Dickson DW, Wszolek ZK. Autosomal dominant Parkinson's disease caused by SNCA duplications. Parkisonism Relat Disord. 2016; 1: S1-6.
Kuo YM, Li Z, Jiao Y, Gaborit N, Pani AK, Orrison BM, et al. Extensive enteric nervous system abnormalities in mice transgenic for artificial chromosomes containing Parkinson disease-associated alpha-synuclein gene mutations precede central nervous system changes. Hum Mol Genet 2010; 19(9): 1633-50.
Lang AE, Lozano AM. Parkinson's disease. First of two parts. N Engl J Med. 1998; 339(15): 1044-53.
Luk KC, Kehm V, Carroll J, Zhang B, O'Brien P, Trojanowski JQ, et al. Pathological α- synuclein transmission initiates Parkinson-like neurodegeneration in nontransgenic mice. Science 2012; 338(6109): 949-53.
Macchi F, Deleersnijder A, Van den Haute C, Munck S, Pottel H, Michiels A, et al. High- content analysis of α-synuclein aggregation and cell death in a cellular model of Parkinson's disease. J Neurosci Methods 2016; 261: 117-27.
Maesako M, Uemura K, Kubota M, Kuzuya A, Sasaki K, Hayashida N, et al. Exercise is more effective than diet control in preventing high fat diet-induced β-amyloid deposition and memory deficit in amyloid precursor protein transgenic mice. J Biol Chem 2012; 287(27): 23024-33.
Maraganore DM, de Andrade M, Elbaz A, Farrer MJ, Ioannidis JP, Krüger R, et al. Collaborative analysis of alpha-synuclein gene promoter variability and Parkinson disease. JAMA 2006; 296(6): 661-70.
Martin ZS, Neugebauer V, Dineley KT, Kayed R, Zhang W, Reese LC, et al. α-Synuclein oligomers oppose long-term potentiation and impair memory through a calcineurin-dependent mechanism: relevance to human synucleopathic diseases. J Neurochem 2012; 120(3): 440–52.
Masuda-Suzukake M, Nonaka T, Hosokawa M, Kubo M, Shimozawa A, Akiyama H, et al. Pathological alpha-synuclein propagates through neural networks. Acta Neuropathologica Communications 2014; 2(1): 1-12.
Masuda-Suzukake M, Nonaka T, Hosokawa M, Oikawa T, Arai T, Akiyama H, et al. Prion-like spreading of pathological α-synuclein in brain. Brain 2013; 136(4): 1128-38.
McDowll KA, Shin D, Roos KP, Chesselet MF. Sleep dysfunction and EEG alterations in mice overexpressing alpha-synuclein. J Parkinsons Dis 2014; 4(3): 531-9.
Mor DE, Tsika E, Mazzulli JR, Gould NS, Kim H, Doshi S et al. Dopamine induces soluble α-synuclein oligomers and nigrostriatal degeneration. Nat Neurosci. 2017; 20(11): 1560-8.
Nuber S, Harmuth F, Kohl Z, Adame A, Trejo M, Schonig K, et al. A progressive dopaminergic phenotype associated with neurotoxic conversion of alpha-synuclein in BAC-transgenic rats. Brain 2013; 136(Pt 2): 412-32.
Olgiati S, Thomas A, Quadri M, Breedveld GJ, Graafland J, Eussen H, et al. Early-onset parkinsonism caused by alpha-synuclein gene triplication: Clinical and genetic findings in a novel family. Parkinsonism & Related Disorders 2015; 21(8): 981-6.
Ono K. The oligomer hypothesis in α-synucleinopathy. Neurochem Res. 2017; 42(12): 3362- 71.
Outeiro TF, Putcha P, Tetzlaff JE, Spoelgen R, Koker M, Carvalho F, et al. Formation of toxic oligomeric alpha-synuclein species in living cells. PLoS One 2008; 3(4): e1867.
Peever J, Luppi PH, Montplaisir J. Breakdown in REM sleep circuitry underlies REM sleep behaveor disorder. Trends Neurosci 2014; 37(5):279-88.
Plotegher N, Berti G, Ferrari E, Tessari I, Zanetti M, Lunelli L, et al. DOPAL derived alpha- synuclein oligomers impair synaptic vesicles physiological function. Sci Rep 2017; 7: 40699.
Poewe W, Seppi K, Tanner CM, Halliday GM, Brundin P, Volkmann J, et al. Parkinson disease. Nature Reviews Disease Primers 2017; 3: 17013.
Postuma RB, Aarsland D, Barone P, Burn DJ, Hawkes CH, Oertel W, et al. Identifying prodromal Parkinson's disease: pre-motor disorders in Parkinson's disease. Mov Disord 2012; 27(5): 617-26.
Postuma RB, Berg D. Advances in markers of prodromal Parkinson disease. Nat Rev Neurol 2016; 12(11): 622-34.
Rockenstein E, Nuber S, Overk CR, Ubhi K, Mante M, Patrick C, et al. Accumulation of oligomer-prone α-synuclein exacerbates synaptic and neuronal degenerateon. Brain 2014; 137(Pt 5): 1496-513.
Rodriguez JA, Ivanova MI, Sawaya MR, Cascio D, Reyes FE, Shi D, et al. Structure of the toxic core of α-synuclein from invisible crystals. Nature 2015; 525(7570): 486-90.
Rothman SM, Griffioen KJ, Vranis N, Ladenheim B, Cong WN, Cadet JL, et al. Neuronal expression of familial Parkinson’s disease A53T α-synuclein causes early motor impairment, reduced anxiety and potential sleep disturbances in mice. J Parkinsons Dis 2013; 3(2):215-9.
Satake W, Nakabayashi Y, Mizuta I, Hirota Y, Ito C, Kubo M, et al. Genome-wide association study identifies common variants at four loci as genetic risk factors for Parkinson's disease. Nature genetics 2009; 41(12): 1303-7.
Schapira A, Chaudhuri RK, Jenner P. Non-motor features of Parkinson disease. Nature Reviews Neuroscience 2017; 18(7): 435-50.
Sharon R, Bar-Joseph I, Frosch MP, Walsh DM, Hamilton JA, Selkoe DJ. The formation of highly soluble oligomers of alpha-synuclein is regulated by fatty acids and enhanced in Parkinson’s disease. Neuron 2003; 37(4): 583–95.
Spillantini MG, Crowther RA, Jakes R, Hasegawa M, Goedert M. α-Synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with Lewy bodies. Proceedings of the National academy of sciences 1998.
Spillantini MG, Schmidt ML, Lee VM, Trojanowski JQ, Jakes R, Goedert M. Alpha-synuclein in Lewy bodies. Nature 1997; 388(6645): 839-40.
Spira PJ, Sharpe DM, Halliday G, Cavanagh J, Nicholson GA. Clinical and pathological features of a Parkinsonian syndrome in a family with an Ala53Thr alpha-synuclein mutation. Ann Neurol 2001; 49(3): 313-9.
Takeda A, Hashimoto M, Mallory M, Sundsumo M, Hansen L, Masliah E. C-terminal alpha- synuclein immunoreactivity in structures other than Lewy bodies in neurodegenerative disorders. Acta neuropathologica 2000; 99(3): 296-304.
Tanji K, Mori F, Mimura J, Itoh K, Kakita A, Takahashi H, et al. Proteinase K-resistant α- synuclein is deposited in presynapses in human Lewy body disease and A53T α-synuclein transgenic mice. Acta Neuropathologica 2010; 120(2): 145-54.
Taylor TN, Potgieter D, Anwar S, Senior SL, Janezic S, Threlfell S, et al. Region-specific deficits in dopamine, but not norepinephrine, signaling in a novel A30P alpha-synuclein BAC transgenic mouse. Neurobiol Dis 2014; 62: 193-207.
Tran HT, Chung C, Iba M, Zhang B, Trojanowski JQ, Luk KC, et al. A-Synuclein immunotherapy blocks uptake and templated propagation of misfolded α-synuclein and neurodegeneration. Cell reports 2014; 7(6): 2054-65.
Turmaine M, Raza A, Mahal A, Mangiarini L, Bates GP, Davies SW. Nonapoptotic neurodegeneration in a transgenic mouse model of Huntington's disease. Proc Natl Acad Sci U S A 2000; 97(14): 8093-7.
Uchiyama M, Isse K, Tanaka K, Yokota N, Hamamoto H, Aida S, et al. Incidental Lewy body disease in a patient with REM sleep behavior disorder. Neurology 1995; 45(4): 709–12.
Uemura N, Yagi H, Uemura MT, Hatanaka Y, Yamakado H, Takahashi R. Inoculation of α- synuclein preformed fibrils into the mouse gastrointestinal tract induces Lewy body-like aggregates in the brainstem via the vagus nerve. Molecular neurodegeneration 2018; 13(1): 21.
Vaikath NN, Majbour NK, Paleologou KE, Ardah MT, van Dam E, van de Berg WD et al. Generation and characterization of novel conformation-specific monoclonal antibodies for α-synuclein pathology. Neurobiol Dis. 2015; 79: 81-99.
Valencia Garcia S, Brischoux F, Clément O, Libourel PA, Arthaud S, Lazarus M3, et al. Ventromedial medulla inhibitory neuron inactiveation induces REM sleep without atonia and REM sleep behavior disorder. Nat Commun 2018; 9(1): 504.
Valencia Garcia S, Libourel PA, Lazarus M, Grassi D, Luppi PH, Fort P. Genetic inactiveation of glutamate neurons in the rat subletrodorsal tegmental nucleus recapitulates REM sleep behavior disorder. Brain 2017; 140(2):414-28.
Visanji NP, Brotchie JM, Kalia LV, Koprich JB, Tandon A, Watts JC, et al. α-Synuclein-Based Animal Models of Parkinson's Disease: Challenges and Opportunities in a New Era. Trends in Neurosciences 2016; 39(11): 750-62.
Wan OW, Chung KKK. The role of alpha-synuclein oligomerization and aggregation in cellular and animal models of Parkinson's disease. PloS one 2012; 7(6).
Wersinger C, Sidhu A. Disruption of the interaction of α-synuclein with microtubules enhances cell surface recruitment for the dopamine transporter. Biochemistry 2005; 44(41): 13612-24.
Winner B, Jappelli R, Maji SK, Desplats PA, Boyer L, Aigner S, et al. In vivo demonstration that α-synuclein oligomers are toxic. Proc Natl Acad Sci USA 2011; 108(10): 4194–9.
Yamakado H, Moriwaki Y, Yamasaki N, Miyakawa T, Kurisu J, Uemura K, et al. α-Synuclein BAC transgenic mice as a model for Parkinson's disease manifested decreased anxiety-like behavior and hyperlocomotion. Neuroscience Research 2012; 73(2): 173-7.
Zhang S, Xiao Q, Le W. Olfactory dysfunction and neurotransmitter disturbance in olfactory bulb of transgenic mice expressing human A53T mutant alpha-synuclein. PLoS One 2015; 10(3): e0119928.
論文の公開元へ
